Christopher R. Stone

Array ( [id] => 10324358 [patent_doc_number] => 20150209362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/621808 [patent_app_country] => US [patent_app_date] => 2015-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15900 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10405148 [patent_doc_number] => 20150290157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-15 [patent_title] => 'TRANEXAMIC ACID FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 14/620672 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 18689 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14620672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12543039 [patent_doc_number] => 10010547 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-03 [patent_title] => Pharmaceutical compounds [patent_app_type] => utility [patent_app_number] => 15/118072 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49939 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 979 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15118072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10311517 [patent_doc_number] => 20150196519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'Acetylcysteine Composition and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/616507 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4315 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14616507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11031495 [patent_doc_number] => 20160228452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-11 [patent_title] => 'TREATMENT OF METABOLIC DISEASES BY INHIBTION OF HTR2A OR HTR3' [patent_app_type] => utility [patent_app_number] => 14/611143 [patent_app_country] => US [patent_app_date] => 2015-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 13211 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14611143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10325707 [patent_doc_number] => 20150210708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'NOVEL TRICYCLIC COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 14/610119 [patent_app_country] => US [patent_app_date] => 2015-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 136560 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14610119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10263431 [patent_doc_number] => 20150148427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS' [patent_app_type] => utility [patent_app_number] => 14/607526 [patent_app_country] => US [patent_app_date] => 2015-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10907 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14607526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106243 [patent_doc_number] => 09862713 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Substituted bicyclic heteroaryl compounds as RXR agonists' [patent_app_type] => utility [patent_app_number] => 15/111585 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 79 [patent_no_of_words] => 54618 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10387960 [patent_doc_number] => 20150272967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-01 [patent_title] => 'EXTREMELY HIGH LOADING DOSE' [patent_app_type] => utility [patent_app_number] => 14/584036 [patent_app_country] => US [patent_app_date] => 2014-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10396 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14584036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10324341 [patent_doc_number] => 20150209345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE' [patent_app_type] => utility [patent_app_number] => 14/581462 [patent_app_country] => US [patent_app_date] => 2014-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19511 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14581462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10273886 [patent_doc_number] => 20150158882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-11 [patent_title] => 'HETEROCYCLIC COMPOUND' [patent_app_type] => utility [patent_app_number] => 14/566157 [patent_app_country] => US [patent_app_date] => 2014-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 118056 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14566157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364019 [patent_doc_number] => 20170002000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/104659 [patent_app_country] => US [patent_app_date] => 2014-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32095 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15104659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11066146 [patent_doc_number] => 20160263110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'USE OF MASITINIB FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS' [patent_app_type] => utility [patent_app_number] => 15/033797 [patent_app_country] => US [patent_app_date] => 2014-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9453 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15033797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9951242 [patent_doc_number] => 09000029 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-07 [patent_title] => 'Proline sulfonamide derivatives as orexin receptor antagonists' [patent_app_type] => utility [patent_app_number] => 14/530532 [patent_app_country] => US [patent_app_date] => 2014-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 16908 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14530532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9910288 [patent_doc_number] => 20150065489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'Substituted Quinolines and Their Use As Medicaments' [patent_app_type] => utility [patent_app_number] => 14/528456 [patent_app_country] => US [patent_app_date] => 2014-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36745 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14528456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10220446 [patent_doc_number] => 20150105439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES' [patent_app_type] => utility [patent_app_number] => 14/516543 [patent_app_country] => US [patent_app_date] => 2014-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13925 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14516543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10202898 [patent_doc_number] => 20150087886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-26 [patent_title] => 'NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/510476 [patent_app_country] => US [patent_app_date] => 2014-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 20359 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14510476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10214810 [patent_doc_number] => 20150099802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-09 [patent_title] => 'SELECTIVE TUMOR TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/503922 [patent_app_country] => US [patent_app_date] => 2014-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7134 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14503922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9932238 [patent_doc_number] => 20150080430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-19 [patent_title] => 'USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/497020 [patent_app_country] => US [patent_app_date] => 2014-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12219 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14497020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10547348 [patent_doc_number] => 09271948 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Agent for improving vesicourethral dyssynergia' [patent_app_type] => utility [patent_app_number] => 14/496281 [patent_app_country] => US [patent_app_date] => 2014-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 4272 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14496281 [rel_patent_id] =>[rel_patent_doc_number] =>)